Article metrics

Download PDFPDF

368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to May 2022

AbstractFullPdf
Nov 2020339032
Dec 2020129021
Jan 202150012
Feb 202140016
Mar 202186022
Apr 202178012
May 202129010
Jun 20210010
Jul 20210018
Aug 20210015
Sep 20210012
Oct 2021108036
Nov 2021120027
Dec 20216608
Jan 2022124011
Feb 2022116012
Mar 202292010
Apr 202215008
May 202210009
Total16270301